These findings, researchers wrote, suggest that artificial sweeteners "should not be considered a healthy and safe alternative to sugar."

All-cause mortality after five years is much more likely if a TAVR patient presents with CAD, according to a new analysis published in JACC: Cardiovascular Interventions.

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

Researchers tracked data from more than 2,000 patients, noting that surgical bailout, infective endocarditis and paravalvular leak were the most common reasons for surgery to be required after TAVR. The full study was published in the American Journal of Cardiology.

A 31-year-old patient developed acute myocarditis shortly after the onset of monkeypox symptoms. The team that treated him shared their story in a new case study.

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston.